SFM
TARA icon

Sphera Funds Management’s Protara Therapeutics TARA Stock Holding History

Sphera Funds Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-650,000
Closed -$3.46M – 114
2025
Q4 		$3.46M Buy
+650,000
New +$3.61M 0.67% 56

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Sphera Funds Management's TARA Position: Q1 2026 in Review

Sphera Funds Management sold out of Protara Therapeutics (TARA) in Q1 2026, closing a stake of 650,000 shares — an estimated $3.46M sold.

Sphera Funds Management first reported a position in TARA in Q4 2025 and held it in 1 quarter. The position peaked at $3.46M in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Sphera Funds Management reported no remaining Protara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sphera Funds Management sold 650,000 Protara Therapeutics shares in Q1 2026, an estimated $3.46M.
  • Sphera Funds Management first reported a position in Protara Therapeutics in Q4 2025 and held it in 1 quarter.
  • Sphera Funds Management's Protara Therapeutics position peaked at $3.46M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.